Evidence map›Paper›PMID 27053769›Full record

Trial reportSocial cognitive and affective neuroscience2016

Oxytocin, but not vasopressin, impairs social cognitive ability among individuals with higher levels of social anxiety: a randomized controlled trial.

Benjamin A Tabak, Meghan L Meyer, Janine M Dutcher, Elizabeth Castle, Michael R Irwin, Matthew D Lieberman, Naomi I Eisenberger

Registry-linked trialOpen access · bronzeAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Social cognitive and affective neuroscience, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01680718 (Neuropeptides and Social Behavior), which is not on this map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
6.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01680718 early_phase1completednot on this map

Neuropeptides and Social Behavior

TypeinterventionalSponsorUniversity of California, Los AngelesRan2012 to 2013Enrolled160ConditionsSocial PsychologyArmsIntranasal oxytocin, Intranasal vasopressin, Intranasal placebo
3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 26 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Social Working Memory: a Systematic Review.Neuropsychology review · 2026
    Review
  6. Article
  7. A role for theThe American journal of drug and alcohol abuse · 2020
    Article
  8. Article
  9. Review
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Benjamin A TabakDepartment of Psychology btabak@psych.ucla.edu.
Meghan L MeyerDepartment of Psychology.
Janine M DutcherDepartment of Psychology.
Elizabeth CastleDepartment of Psychology.
Michael R IrwinDepartment of Psychology Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine Cousins Center for Psychoneuroimmunology, David Geffen School of Medicine Semel Institute for Neuroscience, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.
Matthew D LiebermanDepartment of Psychology Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine.
Naomi I EisenbergerDepartment of Psychology.
University of California, Los Angeles · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Individuals with social anxiety are characterized by a high degree of social sensitivity, which can coincide with impairments in social cognitive functioning (e.g. theory of mind). Oxytocin (OT) and vasopressin (AVP) have been shown to improve social cognition, and OT has been theorized as a potential therapeutic agent for individuals with social anxiety disorder. However, no study has investigated whether these neuropeptides improve social cognitive ability among socially anxious individuals. In a randomized, double-blind, placebo controlled, between-subjects design we investigated whether social anxiety moderated the effects of OT or AVP (vs placebo) on social working memory (i.e. working memory that involves manipulating social information) and non-social working memory. OT vs placebo impaired social working memory accuracy in participants with higher levels of social anxiety. No differences were found for non-social working memory or for AVP vs placebo. Results suggest that OT administration in individuals with higher levels of social anxiety may impair social cognitive functioning. Randomized-controlled trial registration: NCT01680718.

Indexed as

Phobia, SocialSocial PerceptionAdolescentAdultDouble-Blind MethodFemaleHumansMaleMemory, Short-TermOxytocinVasopressinsYoung AdultOxytocinVasopressinsoxytocinsocial anxietysocial cognitionsocial working memoryvasopressin

Identifiers

PMID27053769
PMCPMC4967803
OpenAlexW2324079089

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.